MediPharm Labs - LABS (Seite 9)

eröffnet am 13.08.19 08:35:24 von
neuester Beitrag 16.11.20 16:20:50 von


Beitrag schreiben

Begriffe und/oder Benutzer

 

Avatar
24.07.20 14:44:24
Cannabisunternehmen
MediPharm Labs (LABS.TO) (MEDIF) ist ein führendes kanadisches Cannabisunternehmen, das in hohem Maße auf dem Cannabisölmarkt tätig ist. Das Unternehmen betreibt eine hochmoderne EU-GMP-Einrichtung, mit der es sowohl vom nationalen als auch vom internationalen Cannabismarkt profitieren kann.

MediPharm ist im letzten Jahr unter erheblichen Druck geraten und wir glauben, dass der Markt die Gelegenheit verpasst. Anfang dieses Monats nahm Canaccord Genuity die Berichterstattung über MediPharm mit einem spekulativen Kaufrating und einem Kursziel von 2,25 USD wieder auf. Das Kursziel impliziert, dass MediPharm mehr als 100% des aktuellen Niveaus aufweist, und wir finden dies von Bedeutung.

Im vergangenen Monat senkte Altacorp an PI Financial die Preisziele für MediPharm auf 2,15 USD bzw. 1,75 USD. Bei diesen niedrigeren Kurszielen gibt es immer noch einen erheblichen Aufwärtstrend beim aktuellen Aktienkurs, und wir glauben, dass unsere Leser sich dessen bewusst sein müssen. In Zukunft verfügt MediPharm über bedeutende potenzielle Katalysatoren für Wachstum und wir glauben, dass es ein günstiges Risiko-Ertrags-Profil aufweist.



Gruß
MediPharm Labs | 0,698 €
Avatar
15.08.20 15:21:12
MediPharm Labs | 0,616 €
Avatar
05.10.20 14:04:52
Das ist ein Brett und Durchbruch Partner Witz STADA

European Pharmaceutical Company STADA Enters Exclusive Medical Cannabis Partnership with MediPharm Labs
globenewswire | 05.10.2020 | 11:55
A milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large pharmaceutical company commercializing medical cannabis products

Partnership validates MediPharm Labs’ GMP pharmaceutical-quality cannabis production and, combined with STADA’s 125-year heritage and experienced marketing and sales platform, will meet the growing demand of the medical cannabis market, beginning in Germany – an estimated €1.5 billion market by 2025

STADA CEO Peter Goldschmidt: “This partnership with MediPharm demonstrates STADA’s ambition to be the go-to-partner for Generics, Consumer Health and Specialty Products. With MediPharm, we are collaborating with a very strong partner in the Medical Cannabis field.”
BAD VILBEL, Germany and TORONTO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- As one of the leading European Consumer Healthcare and Generics companies, STADA, with a product presence in 120 countries, has signed an exclusive supply agreement with MediPharm Labs Inc. (“MediPharm”), a wholly owned subsidiary of MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE:MLZ) (“MediPharm Labs” or the “Company”) a global leader in specialized, research-driven pharmaceutical-quality development and manufacture of cannabis API and derivative products to provide medical cannabis products for the European pharma sector.

“Working with MediPharm will meet the needs of pharmacists and patients and deliver on STADA’s purpose of caring for people’s health as a trusted partner,” commented STADA CEO Peter Goldschmidt. “This partnership with MediPharm demonstrates STADA’s ambition to be the go-to-partner for Generics, Consumer Health and Specialty Products.”

Under the terms of the exclusive partnership, MediPharm will supply GMP certified medical cannabis products to STADA, as well as manufacturing, logistics, and regulatory support. STADA will be responsible for commercializing the cannabis products, initially in Germany as well as marketing and medical education utilizing a pharmaceutically experienced field force.

“This partnership is exactly the type of business MediPharm has been pursuing since its inception and a validation of our strategy to deliver GMP-certified cannabis products that can be used in multiple new products in multiple markets around the world,” said Pat McCutcheon, CEO, MediPharm Labs. “This mandate has meaningful revenue potential for MediPharm Labs and we couldn’t be more excited to partner with a company that has the reputation and resources that STADA commands. As a powerhouse in sales and distribution of pharmaceuticals and non-prescription consumer health products, STADA has the ability to become a transformative force in European medical cannabis markets and we are thrilled to be their exclusive partner.”

The partners will initially focus on Germany, before potentially expanding to other European countries and territories. The partnership also signals MediPharm’s entry into the global pharmaceutical industry within a major European market.

With over 83 million inhabitants benefitting from broad access to healthcare services, Germany currently represents an estimated three-quarters of the current EU medical cannabis market.

The Medical Cannabis Network reports the medical cannabis market in Germany is currently valued at between €150m and €175m, despite only around 10% of the 20,000 pharmacies in Germany selling medical cannabis products today. Furthermore, only a limited number of doctors in Germany currently prescribe medical cannabis. With greater awareness and education around the benefits of medical cannabis, the Medical Cannabis Network estimates that Germany’s dominance in the European cannabis market could expand to €1.5bn by 2025.(1)

This is a further milestone for the global cannabis industry as STADA, in partnership with MediPharm, forges the way as a large pharmaceutical company to commercialize medical cannabis products.

Details of the products that STADA will bring to market through this partnership with MediPharm Labs will be unveiled in the coming months in the respective relevant communication channels.

(1) https://www.healtheuropa.eu/exploring-growth-in-the-european…

Conference Call Webcast
In connection with the announcement of this partnership, MediPharm Labs senior management invite investors and analysts to join a conference call and audio webcast on Monday, October 5, 2020 at 10:30 a.m. Eastern Time.

Participants are asked to dial in approximately 10 minutes before the start of the call using one of the following numbers: Toll-free: +1-833-502-0471; International: +1-236-714-2179.

An audio webcast will be available in the Events section of the MediPharm Labs’ Investor Relations website https://ir.medipharmlabs.com/news-events or by visiting the following link: https://event.on24.com/wcc/r/2737009/88874C24DAD9B53A59DFCAA…

Conference Call Webcast Replay
A replay will be available approximately one hour after the call ends until 12:00 AM ET October 5, 2020 by dialing: Toll-free: +1-833-502-0471; International or +1-236-714-2179. Conference ID: 5093918.

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two-pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2019, STADA achieved adjusted Group sales of EUR 2,608.6 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 625.5 million. STADA employs more than 12,400 people worldwide.
MediPharm Labs | 0,610 €
Avatar
05.10.20 14:06:48
Die MK sollte sich damit kurzfristig locker verfünffachen 💥💥💥🚀🚀😳🤩
MediPharm Labs | 0,610 €
Avatar
16.11.20 16:14:17
- 25 Prozent! Was hier los?
MediPharm Labs | 0,560 C$
Avatar
16.11.20 16:20:50
Gefunden. Umsatzeinbruch
MediPharm Labs | 0,570 C$


Beitrag zu dieser Diskussion schreiben

MediPharm Labs - LABS